Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Apr 27;5(9):a017863.
doi: 10.1101/cshperspect.a017863.

Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis

Kwonjune J Seung  1 , Salmaan Keshavjee  1 , Michael L Rich  1
Affiliations
Review

Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis

Kwonjune J Seung et al. Cold Spring Harb Perspect Med. .

Abstract

The continuing spread of drug-resistant tuberculosis (TB) is one of the most urgent and difficult challenges facing global TB control. Patients who are infected with strains resistant to isoniazid and rifampicin, called multidrug-resistant (MDR) TB, are practically incurable by standard first-line treatment. In 2012, there were approximately 450,000 new cases and 170,000 deaths because of MDR-TB. Extensively drug-resistant (XDR) TB refers to MDR-TB strains that are resistant to fluoroquinolones and second-line injectable drugs. The main causes of the spread of resistant TB are weak medical systems, amplification of resistance patterns through incorrect treatment, and transmission in communities and facilities. Although patients harboring MDR and XDR strains present a formidable challenge for treatment, cure is often possible with early identification of resistance and use of a properly designed regimen. Community-based programs can improve treatment outcomes by allowing patients to be treated in their homes and addressing socioeconomic barriers to adherence.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Percentage of new TB cases with MDR-TB (WHO 2013a).
Figure 2.
Figure 2.
Amplifier effect of short-course chemotherapy. H, isoniazid; R, rifampicin; E, ethambutol; Z, pyrazinamide; S, streptomycin.
Figure 3.
Figure 3.
Designing an MDR-TB regimen. (Created from data in Varaine and Rich 2013.)
See this image and copyright information in PMC

References

    1. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona J, Becerra M, Benedetti A, Burgos M, Centis R, et al. 2012. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: An individual patient data meta-analysis of 9,153 patients. PLoS Med 9: e1001300. - PMC - PubMed
    1. Becerra M, Franke MF, Appleton SC, Joseph JK, Bayona J, Atwood SS, Mitnick CD. 2013. Tuberculosis in children exposed at home to multidrug-resistant tuberculosis. Pediatr Infect Dis J 32: 115–119. - PubMed
    1. Cegielski JP. 2010. Extensively drug-resistant tuberculosis: “There must be some kind of way out of here”. Clin Infect Dis 50: S195–S200. - PubMed
    1. Centers for Disease Control and Prevention (CDC). 2013. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis. MMWR Recomm Rep 62: 1–12. - PubMed
    1. Chavez Pachas AM, Blank R, Fawzi Smith MC, Bayona J, Becerra M, Mitnick CD. 2004. Identifying early treatment failure on category I therapy for pulmonary tuberculosis in Lima Ciudad, Peru. Int J Tuberc Lung Dis 8: 52–58. - PubMed

MeSH terms